Accumulating evidence shows that genetic mutations in cancer-driver genes, tumor suppressors, and amplified oncogenes are linked to specific alterations in metabolic pathways in cancer cells, involving proteins such as isocitrate dehydrogenase (IDH), fumarate hydratase (FH), MYC, K-RAS and BRAF (Levine and Puzio-Kuter, 2010; Cairns et al., 2011; Cheong et al., 2012; Dejure and Eilers, 2017; Palm and Thompson, 2017). This evidence concerns the gene MYC and cancer.